{
    "root": "a33eb37f-c69b-41f3-9d18-540bfd226aa6",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "BRISDELLE",
    "value": "20250428",
    "ingredients": [
        {
            "name": "PAROXETINE MESYLATE",
            "code": "M711N184JE"
        },
        {
            "name": "CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS",
            "code": "L11K75P92J"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "GELATIN",
            "code": "2G86QN327L"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "FD&C RED NO. 3",
            "code": "PN2ZH5LOQY"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        }
    ],
    "indications": "brisdelle indicated treatment moderate severe vasomotor symptoms ( vms ) associated menopause . limitations : brisdelle indicated treatment psychiatric condition . brisdelle lower recommended paroxetine used treat major depressive disorder , obsessive compulsive disorder , panic disorder , generalized anxiety disorder , social anxiety disorder , post-traumatic stress disorder . safety effectiveness lower brisdelle established psychiatric condition . patients require paroxetine treatment psychiatric condition discontinue brisdelle initiate paroxetine-containing product indicated .",
    "contraindications": "recommended brisdelle 7.5 mg daily , bedtime ( 2.1 )",
    "warningsAndPrecautions": "brisdelle ( paroxetine ) capsules available 7.5 mg pink capsules printed black edible ink “ brisdelle ” “ 7.5 mg ” . ndc 83107-027-30 blister packs 30 store 20°-25°c ( 68°-77°f ) ; excursions permitted 15°-30°c ( 59°-86°f ) . protect light humidity .",
    "adverseReactions": "brisdelle contraindicated patients : taking , within 14 days stopping , maois ( including maois linezolid intravenous methylene blue ) increased risk serotonin syndrome [ ( 5.2 ) , interaction ( 7 ) ] . taking thioridazine risk qt prolongation [ ( 5.3 ) , interaction ( 7 ) ] . taking pimozide risk qt prolongation [ ( 5.3 ) , interaction ( 7 ) ] . known hypersensitivity ( e.g . , anaphylaxis , angioedema , stevens-johnson syndrome ) paroxetine inactive ingredients brisdelle [ ( 6.2 ) ] become pregnant menopausal vms occur pregnancy brisdelle may cause fetal harm [ ( 8.1 ) ] .",
    "indications_original": "BRISDELLE is indicated for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.\n                  \n                     Limitations of Use:\n                  \n                  BRISDELLE is not indicated for the treatment of any psychiatric condition. BRISDELLE has a lower recommended paroxetine dosage than that used to treat major depressive disorder, obsessive compulsive disorder, panic disorder, generalized anxiety disorder, social anxiety disorder, and post-traumatic stress disorder. The safety and effectiveness of the lower BRISDELLE dosage has not been established for any psychiatric condition. Patients who require paroxetine for treatment of a psychiatric condition should discontinue BRISDELLE and initiate a paroxetine-containing product that is indicated for such use.",
    "contraindications_original": "The recommended dosage of BRISDELLE is 7.5 mg once daily, at bedtime ( 2.1 )",
    "warningsAndPrecautions_original": "BRISDELLE (paroxetine) capsules is available as 7.5 mg pink capsules printed with black edible ink with “BRISDELLE” and “7.5 mg”.\n                  NDC 83107-027-30 blister packs of 30\n                  Store at 20°-25°C (68°-77°F); excursions permitted to 15°-30°C (59°-86°F). Protect from light and humidity.",
    "adverseReactions_original": "BRISDELLE is contraindicated in patients:\n                  \n                     Taking, or within 14 days of stopping, MAOIs (including the MAOIs linezolid and intravenous methylene blue) because of an increased risk of serotonin syndrome [see Warnings and Precautions (5.2), Drug Interaction (7)].\n                     Taking thioridazine because of risk of QT prolongation [see Warnings and Precautions (5.3), Drug Interaction (7)].\n                     Taking pimozide because of risk of QT prolongation [see Warnings and Precautions (5.3), Drug Interaction (7)].\n                     With known hypersensitivity (e.g., anaphylaxis, angioedema, Stevens-Johnson syndrome) to paroxetine or to any of the inactive ingredients in BRISDELLE [see Adverse Reactions (6.2)]\n                     \n                     Who are or become pregnant because menopausal VMS does not occur during pregnancy and BRISDELLE may cause fetal harm [see Use in Specific Populations (8.1)]."
}